Hepatitis B Management and Treatment

Kaya Süer

Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology

HBV is a life long, dynamic disease

- Changes over time
- Risk of end stage liver disease and cancer increases with ongoing inflammation and viremia in adults
- Fibrosis can be reversible
- Drugs can decrease fibrosis progression
- HBV can be controlled but not cured
- Reactivation can occur even in those who have lost HBsAg

Who should be tested for HBV?new

- Blood and organs donors
- Hemodialysis patients
- Pregnant women
- Infants of HBsAg + mothers
- Behavioural contacts:
 - Household and sexual contacts
 - HIV+, MSM, IDU
- Individuals from countries where prevalence is ≥2%
- Patients receiving immunosuppressive therapy
- Abnormal ALT of unknown cause


CDC 2008

Hepatitis B: Epidemiology

- HBV very common worldwide, ~350 million infected
- 3 million Turkish carrier (%5 population)
- %1 Cyprus citizen infected with HBV
- HBV is 10x more common in HIV+ than in general population

Keeffe EB, et al. *Clin Gastroenterol Hepatol.* 2006. Nunez M, et al. *Lancet Infect Dis* 2005.

Risk Factors for Hepatitis B



Strategy to Eliminate Hepatitis B Virus Transmission

- Prevent perinatal HBV transmission
- Routine vaccination of all infants
- Vaccination of children in high-risk groups
- Vaccination of adolescents
- Vaccination of adults in high-risk groups

Hepatitis B Vaccine Adolescent and Adult Schedule

<u>Dose</u> Primary 1 Primary 2 Primary 3 Usual interval 0 month 1 month 5 month

Hepatitis B Vaccine


Routine booster doses are <u>NOT</u> routinely recommended for any group

Global Patterns of Chronic HBV Infection


- High (>8%): 45% of global population
 - lifetime risk of infection >60%
 - early childhood infections common
- Intermediate (2%-7%): 43% of global population

 lifetime risk of infection 20%-60%
 infections occur in all age groups
- Low (<2%): 12% of global population
 - lifetime risk of infection <20%
 - most infections occur in adult risk groups

Geographic Distribution of HBV Cases



Geographic Distribution of HBV Genotypes



Clinical-Epidemiologic Correlations


HBV Endemicity	Location	Age of Infection	Mode of Transmission	Chronicity	HCC Risk
High 10-15%	Asia Sub-Sahara Africa	Birth Toddler	Perinatal Horizontal	Likely	High
Low < 2%	N. America W. Europe Scandinavia	Early Adulthood	Percutaneous Sexual	Rare	Low



Available at: <u>http://www.who.int/mediacentre/factsheets/fs204/en/</u>. Accessed February 6, 2006. Designed by Jules Dienstag, MD

clinicaloptions.com/hep

Outcomes of Acute HBV Infection



Risk is Related to Age at Infection			
Outcome	Neonates, %	Children, %	Adults, %
Chronic carrier	90	20	< 5
Recover	10	80	> 95


Juszczyk J. Vaccine. 2000;18(suppl 1):S23-S25.

clinicaloptions.com/hep


Hepatitis B Complications

- Fulminant hepatitis
- Hospitalization
- Cirrhosis
- Hepatocellular carcinoma
- Death


Risk of Chronic HBV Carriage by Age of Infection




Natural History of Chronic HBV Infection



Who should be considered for treatment?



Natural History of Chronic HBV Infection




clinicaloptions.com/hep


Possible Outcomes of HBeAg+ Chronic HBV Infection

Patient Populations in Chronic Hepatitis B					
Marker	Immune Tolerant	HBeAg+ CHB	Inactive HBsAg Carrier	HBeAg– CHB (Precore Mutant)	
HBsAg	+	+	+	+	
HBeAg	+	+	Η	—	
Anti-HBe	—	_	+	+	
ALT	Normal	\uparrow	Normal	\uparrow	
HBV DNA (copies/mL)	> 10 ⁵	> 10 ⁵	< 10 ³	> 10 ⁴	
Histology	Normal/Mild	Active	Normal	Active	

Annual Risk of HBV Progression




HBV DNA Level and Risk of HCC



HBV DNA (copies/ml)	Cumulative incidence of HCC
<300	1.30
300-9999	1.37
10,000-99,999	3.57
100,000-999,999	12.17
>1 million	14.89

Chen C-J. JAMA 2006; 295:67-73.

Overview of Algorithm Used to Determine Need for Treatment of HBV



Keeffe EB, et al. *Clin Gastroenterol Hepatol.* 2008 Lok AS et al Hepatology, St0092

HBV Treatment Guidelines

HBeAg	HBV DNA (IU/mI)*	ALT	Management
+	< 20,000	Normal [#]	Follow, no treatment
+	≥ 20,000	Normal	Consider biopsy; treat if diseased
+	≥ 20,000	Elevated	Treat
_	< 2,000	Normal	Follow, no treatment
_	≥ 2,000	Normal	Consider biopsy; treat if diseased
—	≥ 2,000	Elevated	Treat

*1 IU = 5.6 copies; #Normal ALT for men = 30 U/ml and for women = 19 U/ml Keeffe EB, et al. *Clin Gastroenterol Hepatol.*2006.


Goals of Therapy in Patients With Chronic HBV Infection

- Eradication of infection
 - HBsAg seroconversion
 - Undetectable HBV DNA
- Prevent complications of liver disease
 - Histologic progression to cirrhosis
 - Decompensated liver disease
 - Liver cancer

Therapeutic Endpoints

- HBeAg-positive patients (wild type)
 - HBeAg seroconversion is KEY
 - Sustained suppression of HBV DNA to low or undetectable levels
 - ALT normalization
 - Reduced necroinflammation on biopsy
- HBeAg-negative patients (precore and core promoter mutants)
 - HBeAg seroconversion not an endpoint
 - Sustained suppression of HBV DNA to low or undetectable levels
 - ALT normalization
 - Reduced necroinflammation on biopsy


Therapeutic endpoints over time



HBV Control

- Inflammatory: normalize serum ALT, biopsy
- Virologic: decrease HBV DNA
- Immune: seroconversion
 - HBeAg to HBeAb
 - HBsAg to HBsAb
- HBV never "cured" but controlled

Timeline for FDA-Approved Agents used to Treat HBV



Timeline for FDA-Approved Agents used to Treat HBV

Medication	Trade Name	Dose
Interferon alfa-2b	Intron A	5 million IU sq once daily or 10 million IU sq 3x/week
Peginterferon alfa-2a	Pegasys	180 mcg sq once weekly
Lamivudine (3TC)	<i>Zeffix,HBV</i> (100 mg) <i>Epivir</i>	100 mg PO once daily 300 mg PO once daily for HIV-infected
Adefovir (ADV)	Hepsera	10 mg PO once daily
Entecavir (ETV)	Baraclude	0.5 mg PO once daily: treatment-naïve 1 mg PO once daily: lamivudine resistance
Telbivudine (LdT)	Tyzeka	600 mg PO once daily
Tenofovir (TDF)	Viread	300 mg PO once daily

Abbreviations: IU = international units; sq = subcutaneously qd = once daily bid = twice daily

Lamivudine (3TC, Zeffix, Epivir)

- Nucleoside analog
- Different dose for HBV (100 mg) monotherapy
- Well-tolerated and cheap
- HBeAg conversion rate b/t 21-28%
- High rates of resistance!

 47% develop YMDD mutation at 2 yrs, 90% at 4 yrs

Adefovir (Hepsera)

- Nucleotide analog
- At 10 mg/d dose
- Effective for LAM resistant HBV, no crossresistance
- Side effects: renal toxicity, Fanconi's Syndrome

Tenofovir (Viread)

- Nucleotide analog for HBV
- Perhaps more potent than Adefovir
 48 wk moon decline in HBV DNA (log10)
 - 48 wk mean decline in HBV DNA (log10) 4.4
 vs 3.2
- 63% had HBV suppression by wk 48, 15% had anti-HBe seroconversion
- Rare cases of ADV resistance but TDF sensitivity

Schildgen O. 2006 N Engl J Med 354:1807-12 Peters M. CROI 2005; Abstract 124.

Entecavir (Baraclude)

- Nucleoside analog
- Good for LAM failures
 - 84% of patients had 2 log decline or <400 copies/ml after 24 wks
- Cross-resistance can occur w/ LAM
- Start w/ higher dose (1.0 mg/d) Entecavir in HIV/HBV patients

Peg-interferon alfa 2a/2b (Pegasys,Pegintron)

- Long acting form of IFN, once weekly
- Pros: defined duration (48 wks), low resistance
- Cons: Many side effects, expensive, not for decompensated cirrhosis

Pegintron used for Chronic HBV: Adverse Effects

Adverse Effects

Systemic

- Fever (low grade)
- Myalgias/Arthralgias
- Fatigue

Mood Disturbances

- Depression
- Irritability
- Insomnia

Hematologic

- Neutropenia
- Anemia
- Thrombocytopenia

Endocrine

- Hypothyroidism
- Hyperthyroidism

Dermatologic

- Rash
- Dry skin
- Pruritis
- Thinning of Hair

Gastrointestinal

- Anorexia
- Nausea
- Weight loss

Agents used for Chronic HBV: Cautionary Notes

Cautionary Note

Contraindicated in patients with:

Uncontrolled major depression (especially with past suicide attempts)

- Autoimmune hepatitis or other autoimmune diseases
- Severe cardiovascular disease (e.g. uncontrolled hypertension, coronary artery disease, congestive heart failure)
- Decompensated cirrhosis or hepatocellular carcinoma
- Uncontrolled seizure disorder

Not recommended for first-line anti-HBV therapy because of high resistance rates

Caution in patients with baseline renal insufficiency

Taken on empty stomach (>2 hours before or after a meal); should not use without HIV therapy in HIV-HBV co-infected patients

Caution in patients with baseline renal insufficiency

Interferon alfa-2b and Peginterferon alfa-2a

Medication


Lamivudine (3TC)

Adefovir (ADV)


Entecavir (ETV)

Tenofovir (TDF)

Undetectable HBV DNA Levels after 1 Year of Therapy (HBeAg Positive)



Undetectable HBV DNA Levels after 1 Year of Therapy (HBeAg Negative)



HBV is a dynamic disease

- Diagnose
- Initial evaluation includes education


 Family and sexual contacts should be tested
- Monitor as status changes over time
- Selection of patients to treat

 Individualize treatment decisions
 - $_{\odot}$ Change if no/ poor response
- Long term monitoring

 HCC, special populations, reactivation

HBV: The importance of monitoring

HBV is a dynamic disease!!!



Require monitoring...

- Inactive disease may not remain inactive
- Liver damage may occur if HBV reactivates

HBV can be controlled but not cured